Floatz logo

Membrane-Bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Allogeneic Stem Cell Transplant Recipient

Sumithira VasuCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

75 Active assets in the Allogeneic Stem Cell Transplant Recipient cohort.

Asset / SponsorPhaseRating
Busulphan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2/3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2BBB
Decitabine
Chinese PLA General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Membrane-Bound Interleukin-21-Expanded Haploidentical Natural Killer Cells is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →